Is Even The Pharma Industry Over COVID-19 Already?

Data suggests fewer approvals and new product ideas, as the business case for new generic and brand treatments seems to be tougher to make now than at other times during the pandemic.

COVID-19 pill among other pills
Data suggest fewer new COVID-19 drug development programs are being planned than at the beginning of the pandemic. • Source: Shutterstock

After more than two years ramping up supplies of existing medicines used to treat COVID-19, interest in developing products for the pandemic may be winding down for the brand and generic industries alike.

US Food and Drug Administration data suggests that COVID-19-related generic approvals have mostly declined since peaking during the October-December 2020...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet